Theriva Biologics advances VCN-01 toward Phase 3 trial

Theriva Biologics ( (TOVX) ) just unveiled an announcement.

Theriva Biologics has updated investors on progress preparing a Phase 3 clinical trial for its lead oncolytic virus VCN-01 in first-line metastatic pancreatic cancer, supported by encouraging Phase 2b VIRAGE data showing improved overall and progression-free survival, longer duration of response, and an acceptable safety profile when VCN-01 is added to standard gemcitabine/nab-paclitaxel chemotherapy in a real-world patient population. The company is also advancing VCN-01 in retinoblastoma and other solid tumor indications, reporting multiple regulatory designations in the U.S. and EU, a projected cash runway into the first quarter of 2027, and an active search for financing or partnerships, developments that collectively underscore its bid to strengthen its position in the competitive cancer therapeutics market and to move toward pivotal-stage programs in high-mortality and rare disease settings.

The most recent analyst rating on (TOVX) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, sizable losses, and persistent cash burn with declining equity). Offsetting this are moderately improved near-term technicals and positive corporate developments (EMA-backed Phase 3 path and encouraging data), but valuation support is limited given negative earnings and no dividend data.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics is a clinical-stage oncology company developing unique oncolytic virus therapies, led by its engineered adenovirus candidate VCN-01 for multiple solid tumors including metastatic pancreatic cancer and retinoblastoma. The company, listed on the NYSE American under ticker TOVX and operating from Rockville, Maryland and Barcelona, Spain, is advancing a pipeline that also includes the VCN-X discovery platform and gastrointestinal-focused candidates SYN-004 and SYN-020, while seeking financing and partnerships to support pivotal trials.

Average Trading Volume: 19,007,969

Technical Sentiment Signal: Strong Sell

Current Market Cap: $7.83M

See more data about TOVX stock on TipRanks’ Stock Analysis page.